Schizophrenia News and Research

Latest Schizophrenia News and Research

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson's disease patients.

6 Oct 2010

Centre for Addiction and Mental Health selected as field trial sites for DSM-5 criteria

Toronto's Centre for Addiction and Mental Health (CAMH) has been selected as one of seven adult field trial sites in North America and the only site in Canada to test proposed diagnostic criteria for the American Psychiatric Association's (APA) fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM).

6 Oct 2010

Study may lend insight about hallucination mechanism in schizophrenia

Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.

6 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Galapagos honored with 2010 EUROPEAN BIOTECHNICA AWARD

The Belgian biotech company Galapagos has won the 2010 EUROPEAN BIOTECHNICA AWARD. Galapagos thus secures the lion's share of the prize money totalling 75,000 euros, which is offered every year in the competition staged by Deutsche Messe AG and its partners. The award celebrates innovative European companies from the biotechnology sector and the life sciences.

5 Oct 2010

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Thirteen national and international experts in the field of Brain Stimulation in Psychiatry and Neurology will meet October 7 and 8 during a conference held at the Douglas Mental Health University Institute. They will present research findings and ground-breaking clinical applications concerning the use of brain stimulation techniques. New treatments still under development, such as transcranial magnetic stimulation, will also be discussed. Close to 150 participants are expected to take part in this conference.

5 Oct 2010

Researchers reveal ways to halt Rett Syndrome

In a study published today in the Journal, Proceedings of the National Academy of Sciences, an international team of researchers based in the U.S. and UK revealed that they were able to halt the potentially lethal, breath holding episodes associated with the neurological disease Rett syndrome.

5 Oct 2010

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Building on its worldwide reputation as a leader in neuroscience research, McGill University today joined with two leading Swiss research institutions - the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETHZ) - to enhance neuroscience research in a host of areas, in fields that include pain therapy, Alzheimer's disease, synapse modelling and repair, neuroimmunology and genetic mechanisms of brain diseases.

5 Oct 2010

NIEHS awards grant to study environmental impact on genetic information

The National Institute of Environmental Health Sciences has awarded $2.27 million to Indiana University researcher Joseph Shaw for a five-year study of how the environment alters genetic information through mutation and natural selection.

5 Oct 2010

Drug companies accused of skirting requirement to submit prices

Drug makers frequently ignore a federal requirement that they submit "pricing data needed to calculate discounts on medications prescribed for poor people under Medicaid, federal investigators say in a new report," The New York Times reports.

4 Oct 2010

Otsuka opens Canadian operations

Otsuka Canada Pharmaceutical Inc. has opened its first Canadian office, in the Montreal suburb of Saint-Laurent. This marks a major milestone in the continued growth of Otsuka in North America.

4 Oct 2010

IRSF awards $1.5M in research grants for Rett syndrome treatment

The International Rett Syndrome Foundation (IRSF) announced today that it will award an additional $1.5M in research grants, bringing the 2010 total to $2.15 million for innovative basic and translational research that moves treatments for Rett syndrome a step closer to the clinic.

4 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

CSHL professor receives NIH grant to study mechanism behind autism and schizophrenia

Anthony Zador, Ph.D., Professor of Biology and Program Chair in Neuroscience at Cold Spring Harbor Laboratory (CSHL), has been awarded a $2.17 million, 5-year grant by the National Institutes of Health (NIH)'s Transformative Research Projects Program (T-R01).

1 Oct 2010

Study indicates neurotransmitters are abnormal in people with psychotic illness

There is growing evidence that two neurotransmitters - dopamine and glutamate - are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem-solving.

1 Oct 2010

New approach to prevent psychotic symptoms

New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain. The findings, published in tomorrow's edition of the journal Biological Psychiatry, suggest a new approach to preventing psychotic symptoms, which could lead to better drugs for schizophrenia.

30 Sep 2010

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

There is growing evidence that two neurotransmitters dopamine and glutamate are abnormal in people with psychotic illness, including schizophrenia. Among many other things, these chemicals play a role in cognitive functions, such as memory, learning, and problem solving.

30 Sep 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

Centre for Addiction and Mental Health selected as field trial sites for DSM-5 criteria

Study may lend insight about hallucination mechanism in schizophrenia

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Galapagos honored with 2010 EUROPEAN BIOTECHNICA AWARD

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Researchers reveal ways to halt Rett Syndrome

McGill University joins two leading Swiss research institutions to enhance neuroscience research

NIEHS awards grant to study environmental impact on genetic information

Drug companies accused of skirting requirement to submit prices

Otsuka opens Canadian operations

IRSF awards $1.5M in research grants for Rett syndrome treatment

New SymPath kit measures DBH activity of Sympathetic Nervous System

NIH to award $64M under Transformative Research Projects program

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

CSHL professor receives NIH grant to study mechanism behind autism and schizophrenia

Study indicates neurotransmitters are abnormal in people with psychotic illness

New approach to prevent psychotic symptoms

Study suggests drugs targeting glutamatergic transmission may help treat psychotic illness

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Schizophrenia News and Research

Latest Schizophrenia News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in